BioCryst Pharmaceuticals Inc (BCRX) financials · rev $874.8M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
BioCryst Pharmaceuticals Inc (BCRX) rev $874.8M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $874.8M | $450.7M |
| Cost of Revenue | $19.1M | $12.3M |
| Gross Profit | $855.8M | $438.4M |
| Operating Income | $341.0M | -$2.54M |
| Net Income | $263.9M | -$88.9M |
| EPS (Diluted) | $1.21 | -$0.43 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $514.2M | $490.4M |
| Current Assets | $404.3M | $422.0M |
| Cash & Equivalents | $89.7M | $104.7M |
| Inventory | $5.40M | $31.3M |
| PP&E | $8.78M | $7.78M |
| Total Liabilities | $633.3M | $966.4M |
| Current Liabilities | $196.1M | $160.4M |
| Long-term Debt | N/A | $314.9M |
| Total Debt | N/A | $314.9M† |
| Shareholders' Equity | -$119.2M | -$475.9M |
| Retained Earnings | -$1.51B | -$1.77B |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $347.4M | -$52.0M |
| CapEx | $2.47M | $1.12M |
| Investing Cash Flow | -$13.7M | $52.6M |
| Financing Cash Flow | -$349.9M | -$5.76M |
| Net Change in Cash | -$15.0M | -$6.12M |
| Free Cash Flow | $344.9M | -$53.1M |
FAQ
What is BCRX P/E and revenue?
BioCryst Pharmaceuticals Inc (BCRX) rev $874.8M.
What is BCRX revenue?
BioCryst Pharmaceuticals Inc last cached revenue is $874.8M (FY2025).
Is BCRX profitable?
BioCryst Pharmaceuticals Inc last cached net income is $263.9M (FY2025).
What are BCRX total assets?
BioCryst Pharmaceuticals Inc last cached total assets are $514.2M (FY2025).
What is BCRX free cash flow?
BioCryst Pharmaceuticals Inc last cached free cash flow is $344.9M (FY2025).
Not investment advice. Cached statements, not a live tape.